Treatment of Gum Inflammation in IBD Patients
Oral Crohn's disease with gum inflammation should be managed in conjunction with a specialist in oral medicine, using topical steroids, topical tacrolimus, or intra-lesional steroid injections as first-line therapy, though evidence from randomized controlled trials is lacking 1.
Clinical Approach
Initial Assessment and Diagnosis
When an IBD patient presents with gum inflammation, distinguish between:
- Classical periodontitis from oral microbial dysbiosis
- IBD-related oral manifestations arising from systemic inflammatory activation
- Medication-related gingival changes
The gingival involvement in IBD may represent a separate disease entity from classical gingivitis, driven by systemic inflammatory mechanisms rather than purely local oral dysbiosis 2.
Treatment Strategy
For IBD-Related Oral Crohn's Disease:
Primary interventions (despite absence of RCT evidence) 1:
- Topical corticosteroids applied directly to affected gingival tissues
- Topical tacrolimus for localized lesions
- Intra-lesional steroid injections for persistent areas
- Enteral nutrition as adjunctive therapy
- Infliximab may be considered for refractory cases
For Concurrent Periodontitis:
Non-surgical periodontal therapy (NSPT) is effective and reduces both local and systemic inflammation 3:
- Scaling and root planing
- Professional plaque removal
- Oral hygiene instruction
Evidence shows NSPT in IBD patients with periodontitis significantly reduces:
- Salivary IL-6, IL-17, and TIM-3 levels
- Serum C-reactive protein
- Clinical periodontal parameters 3
Systemic IBD Treatment Considerations
Anti-IL-12/23 biologics (ustekinumab) appear particularly beneficial for periodontal health 4:
- Lower periodontal inflammation scores compared to anti-TNF therapy
- Reduced gingival crevicular fluid IL-6 levels
- No sextants with advanced periodontal inflammation observed in this group
Anti-TNF therapy patients still show periodontal disease activity, suggesting IL-23-dependent pathways may be more critical in the oral-gut immune axis 4.
Critical Pitfalls to Avoid
- Do not delay treatment waiting for microbiological results if oral inflammation is present
- Do not assume all gum inflammation is classical periodontitis—IBD-related oral manifestations require different management
- Do not overlook the bidirectional relationship: periodontal pathogens like Porphyromonas gingivalis and Fusobacterium nucleatum can translocate to the gut and worsen IBD 5, 2
- Do not perform invasive dental procedures without considering antibiotic prophylaxis in immunosuppressed patients 6
Collaborative Management
Coordinate care between gastroenterology and oral medicine/dentistry 1:
- Detect and eradicate infectious oral foci before initiating immunosuppressants or biologics 6
- Implement modified dental treatment protocols for invasive procedures
- Consider antibiotic prophylaxis for dental interventions in immunosuppressed patients
Monitoring and Follow-up
After initiating treatment:
- Reassess periodontal parameters at 3 months if NSPT performed 3
- Monitor for improvement in both oral and systemic inflammatory markers
- Adjust IBD systemic therapy if oral manifestations persist despite local treatment
The key principle: Treating periodontal inflammation may reduce systemic immune activation in IBD, while optimizing IBD control (particularly with IL-12/23 inhibitors) may improve periodontal outcomes 3, 4.